Evaluation of a novel device for monitoring of asthma

Not Applicable

• Conditions: Health Condition 1: null- Asthma

• Registration Number: CTRI/2017/10/010299
• Lead Sponsor: Redecol Limited

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1. Male or female patients aged 18 to 80 years

2. Steroid naïve patients (not taken steroids for 28 days)

3. Patients presenting to the chest clinic

4. Patients able to read and understand the Patient Information Leaflet and Consent Form.

5. Patients able to provide deep inhaled breaths and exhale while holding a tube in their mouth.

6. Patients who will be available for subsequent diagnostic tests to be conducted within 30 days of the first visit to the chest clinic.

7. Patients with a normal Chest X-Ray

Exclusion Criteria

1. Patients who have taken steroid medication in the previous 28 days.

2. Patients with chest infection or other known lung disease in the previous one month.

3. Patients who have taken a short-acting beta 2-agonists in the previous 8 hours, (before baseline test).

4.Patients who have taken Ipratropium bromide in the previous 24 hours, (before baseline test).

5.Patients with no clinically significant haematology, biochemistry or urinalysis results, (before baseline test).

6. Patients who have taken Long-acting beta 2-agonists in the previous 24 hours, (before baseline test).

7. Patients who have taken leukotriene antagonist in the previous 28 days, (before baseline test).

8. Patients who are too unwell to participate in this study e.g. emergency patients, (before baseline test).

9.Participants who, in the opinion of the Investigator, will not be able to participate in the study.

Study & Design

• Study Type: Observational
• Study Design: Not specified